Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same

The present invention provides an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide, as well as a pharmaceutical composition comprising said immunity-inducing agent.

1. 11. An immunity-inducing agent comprising, as an active component, a conjugate comprising (i) a single-chain polynucleotide or a single-chain polynucleotide derivative comprising a CpG motif, and (ii) an antigenic peptide bound thereto via a spacer, wherein the spacer is covalently bound at one end thereof to the single-chain polynucleotide or the single-chain polynucleotide derivative comprising a CpG motif and covalently bound at the other end thereof to the antigenic peptide, wherein the single-chain polynucleotide or the single-chain polynucleotide derivative comprising a CpG motif is not complexed with β-1,3-glucan, wherein the antigenic peptide and the spacer are bound together via a disulfide bond produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer, and wherein the spacer comprises a repeating unit represented by the formula: wherein X represents an oxygen atom or a sulfur atom, wherein each X may be the same or different, R represents any of (CH2)pO, (CH2)qNH, and (CH2CH2O)m, wherein m, p and q each independently represent a natural number of not more than 10, and n represents a natural number of not more than 10.
2. 22. The immunity-inducing agent according to claim 1, wherein the antigenic peptide has an amino acid length of not less than 5 but not more than 30.
3. 33. The immunity-inducing agent according to claim 1, wherein the antigenic peptide has an amino acid length of not less than 8 but not more than 11.
4. 44. The immunity-inducing agent according to claim 1, wherein the single-chain polynucleotide or the single-chain polynucleotide derivative is a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs.
5. 55. The immunity-inducing agent according to claim 1, wherein the single-chain polynucleotide or the single-chain polynucleotide derivative comprising a CpG motif has a nucleotide length of not less than 15 but not more than 40.
6. 66. The immunity-inducing agent according to claim 1, wherein the single-chain polynucleotide or the single-chain polynucleotide derivative comprising a CpG motif has a nucleotide length of not less than 20 but not more than 30.

CROSS REFERENCES TO RELATED APPLICATIONS
This application is the U.S. national phase of PCT/JP2019/038090 filed on Sep. 27, 2019, which claims priority to Japanese Application No. 2018-186093 filed on Sep. 28, 2018, each expressly incorporated herein by reference in its entirety.
STATEMENT REGARDING SEQUENCE LISTING
The sequence listing associated with this application was provided in the corresponding International Patent Application No. PCT/JP2019/038090, which was filed Sep. 27, 2019, in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is 74166_Seq_List_final_20210324_ST25.txt. The text file is 41,869 bytes; was created on Mar. 24, 2021; and was previously submitted as part of International Patent Application No. PCT/JP2019/038090.
TECHNICAL FIELD
The present invention relates to a novel immunity-inducing agent for inducing antigenic peptide-specific immune responses and comprising an antigenic peptide-adjuvant nucleotide conjugate, and a pharmaceutical composition comprising the same.
BACKGROUND ART
The basic principle for the prevention of infection through vaccination is that pseudo-infection is artificially established to induce acquired immunity and to elicit antibody production and cell-mediated immunity against particular pathogens. It is known that in acquired immunity, T and B cells, which are responsible for “memory” in immunity, play key roles, and the diversity of antibody variable regions caused by DNA recombination enables specific immune responses to numerous numbers of antigens. In contrast, innate immunity, which is mainly mediated by phargocytes such as leukocytes, macrophages and dendritic cells, has been conventionally considered to be a non-specific process of phagocytosis of foreign substances and pathogens, and to merely serve as a “stopgap measure” until acquired immunity is established. However, as a result of advances in studies on the molecular mechanisms of innate immunity, it has been clarified that self/non-self-specific recognition takes place also in innate immunity, and that innate immunity is essential for the establishment of acquired immunity. To be more specific, it has been clarified in recent studies that a family of Toll-like receptors (TLRs), present on antigen-presenting cells such as dendritic cells, macrophages and B cells, can respond to various pathogens, induce cytokine production, and induce acquired immunity through, for example, promotion of differentiation of naïve T cells into Th1 cells, and activation of killer T cells.
Pathogens recognized by the series of TLRs are composed of a wide variety of constituents. One of those constituents is a DNA having a CpG motif (CpG DNA), which acts as a ligand for TLR9. A CpG motif is a nucleotide sequence composed of six nucleotides, in which cytosine (C) and guanine (G) are situated side-by-side at the center and flanked by two purine nucleotides and two pyrimidine nucleotides, and are represented by -PuPu-CG-PyPy-(Pu represents a purine nucleotide, and Py represents a pyrimidine nucleotide) (in humans, GTCGTT is also known to have ligand activity for TLR9). This motif is rarely found in mammals, and is found commonly in bacteria (based on frequency as calculated in terms of probability). In mammals, most of rare CpG motifs are methylated. Unmethylated CpG motifs, which are rarely observed in mammals, have potent immunostimulatory activity (refer to e.g., NPLs 1 to 3). CpG DNA incorporated into cells by endocytosis is recognized by TLR9 present in phagosome-like vesicles, and can induce strong Th1 responses. Th1 responses suppress Th2-dominated allergic responses, and also have potent antitumor activity. Therefore, CpG DNA is expected to be used not only for infection prevention but also as an adjuvant for allergic and neoplastic diseases (refer to e.g., NPL 4).
However, when CpG DNA is used as an adjuvant in immunotherapy, the problem is how to deliver CpG DNA into target cells while protecting DNA against degradation by nucleases in cytoplasm or plasma, or against non-specific binding to proteins.
The present inventors have focused their attention on polysaccharides having a β-1,3-glucan backbone (hereinafter also abbreviated as “β-1,3-glucans”) as a novel gene carrier, and found that β-1,3-glucans are capable of forming new types of complexes by binding to various nucleic acids including nucleic acid drugs (e.g., antisense DNA, CpG DNA) (refer to e.g., PTLs 1, 2, and NPLs 5 to 7).
It was found that when β-1,3-glucan naturally existing in a triple helix conformation is dissolved in an aprotic polar organic solvent such as dimethyl sulfoxide (DMSO) or in a 0.1 N or higher alkali solution to allow glucan to be cleaved into single strands, then a single-strand nucleic acid is added, and the solvent is replaced with water or neutralized again, a triple helix complex consisting of one nucleic acid molecule and two β-1,3-glucan molecules is formed. It is considered that in such a triple helix complex, a linkage between the β-1,3-glucan molecules and the nucleic acid molecule is mainly formed by hydrogen bonding and hydrophobic interaction (refer to NPL 8).
The complexation of nucleic acids with β-1,3-glucans, as described above, enabled delivery of nucleic acids into cells while suppressing undesired interactions of nucleic acids with proteins in the body, such as hydrolysis of nucleic acids by nucleases, or non-specific binding of nucleic acids to plasma proteins. The delivery of CpG DNA into cells was succeeded with the use of a complex of β-1,3-glucan and DNA, or a ternary complex containing a protein with antigenicity (refer to e.g., PTLs 3, 4, and NPLs 9 to 11).
However, the aforementioned conventional techniques had some problems as described below. For example, according to the method of producing a β-1,3-glucan/antigenic protein/CpG DNA ternary complex as disclosed in NPL 11, a formyl group is produced on a glucose residue at the side chain of β-1,3-glucan by oxidization with periodic acid, and the formyl group is reacted with an amino group of a peptide with antigenicity (hereinafter also abbreviated as “antigenic peptide”) by reductive amination reaction, so that a complex in which β-1,3-glucan and the antigenic peptide are covalently bound together can be formed. However, this method has a problem of very low yield. In view of such circumstances, according to, for example, the method of producing a β-1,3-glucan/antigenic protein (antigenic peptide)/CpG DNA ternary complex as disclosed in PTL 4, β-1,3-glucan having a formyl group at the side chain thereof and an antigenic peptide are reacted with each other in an aqueous alkaline solution at the same time as, or sequentially followed by, neutralization, so that improvement can be achieved in yield and the reactivity between the formyl group at the side chain of β-1,3-glucan and an amino group of the antigenic peptide. However, since a peptide contains a plurality of amino groups, control of a reaction site is difficult to achieve. Therefore, there is concern that there may occur various problems, such as variation in immunogenicity depending on the reaction site of an antigenic peptide, or difficulty in separation and purification due to complexity of reaction mixtures with β-1,3-glucan. Further, the procedure for forming a β-1,3-glucan/antigenic peptide complex based on the formation of covalent bonding is more complicated than that for forming a β-1,3-glucan/DNA complex through hydrogen bonding. From these viewpoints, the method of producing a β-1,3-glucan/antigenic peptide/CpG DNA ternary complex as disclosed in PTL 4 still has problems with ease of production and the like.
In view of such problems, the present inventors have proposed a peptide/β-1,3-glucan complex having excellent ease of production and high immunostimulatory activity, the complex comprising: a polysaccharide having a β-1,3-glucan backbone; and a peptide/polynucleotide conjugate in which an antigenic peptide is covalently bound to a polynucleotide or polynucleotide derivative, wherein the polynucleotide or polynucleotide derivative of the peptide/polynucleotide conjugate is bound via hydrogen bonding to the polysaccharide having a β-1,3-glucan backbone to form a complex having a triple helix structure consisting of one molecular chain of the polynucleotide or polynucleotide derivative and two molecular chains of the polysaccharide having a β-1,3-glucan backbone (refer to PTL 5). However, PTL 5 is silent about whether the peptide/polynucleotide conjugate, which constitutes the peptide/β-1,3-glucan complex, has per se immunity induction activity.
There are some reports suggestive of the immunity induction activity of conjugates of CpG DNA with antigenic peptides or proteins (refer to NPLs 12, 13). NPL 12 discloses that administration of conjugates of CpG DNA with ovalbumin (OVA) antigen-derived 18- to 24-mer peptides improves OVA antigen presentation in CD8+ T lymphocytes (CTLs), but is not explicitly demonstrative of induction of CTL cytotoxic activity. NPL 13 discloses that administration of conjugates of CpG DNA with OVA antigen proteins induces CTL cytotoxic activity, but those conjugates were injected at a high dose of 10 μg per mouse, and also, production of those conjugates required complicated steps of chemical DNA synthesis, production of antigen proteins through culturing/purification, and conjugation of DNA with antigen proteins. Thus, the technique of NPL 13 has problems with activity at low doses and ease of production
CITATION LIST
Patent Literatures


    PTL 1: International Patent Publication No. WO 01/34207
    PTL 2: International Patent Publication No. WO 02/072152
    PTL 3: Japanese Unexamined Patent Application Publication No. JP 2010-174107
    PTL 4: Japanese Unexamined Patent Application Publication No. JP 2007-70307
    PTL 5: International Patent Publication No. WO 2015/118789


Non Patent Literatures


    NPL 1: Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger. H. Wagner, Adv. Immunol., 73, 329-368 (1999).
    NPL 2: CpG Motifs in Bacterial DNA and Their Immune Effects. M. Krieg, Annu. Rev. Immunol., 20, 709-760 (2002).
    NPL 3: The Discovery of Immunostimulatory DNA Sequence. S. Yamamoto, T. Yamamoto, and T. Tokunaga, Springer Seminars in Immunopathology, 22, 11-19 (2000).
    NPL 4: Standard Immunology, 2nd Edition, Igaku-Shoin Ltd., 333 (2002)
    NPL 5: Molecular Recognition of Adenine, Cytosine, and Uracil in a Single-Stranded RNA by a Natural Polysaccharide: Schizophyllan. K. Sakurai and S. Shinkai, J. Am. Chem. Soc., 122, 4520-4521 (2000).
    NPL 6: Polysaccharide-Polynucleotide Complexes. 2. Complementary Polynucleotide Mimic Behavior of the Natural Polysaccharide Schizophyllan in the Macromolecular Complex with Single-Stranded RNA and DNA. K. Sakurai, M. Mizu and S. Shinkai, Biomacromolecules, 2, 641-650 (2001).
    NPL 7: Dectin-1 Targeting Delivery of TNF-α Antisense ODNs Complexed with B-1,3-glucan Protects Mice from LPS-induced Hepatitis. S. Mochizuki and K. Sakurai, J. Control. Release, 151, 155-161 (2011).
    NPL 8: Structural Analysis of the Curdlan/Poly (cytidylic acid) Complex with Semiempirical Molecular Orbital Calculations. K. Miyoshi, K. Uezu, K. Sakurai and S. Shinkai, Biomacromolecules, 6, 1540-1546 (2005).
    NPL 9: A Polysaccharide Carrier for Immunostimulatory CpG DNAs to Enhance Cytokine Secretion. M. Mizu, K. Koumoto, T. Anada, T. Matsumoto, M. Numata, S. Shinkai, T. Nagasaki and K. Sakurai, J. Am. Chem. Soc., 126, 8372-8373 (2004).
    NPL 10: Protection of Polynucleotides against Nuclease-mediated Hydrolysis by Complexation with Schizophyllan. M. Mizu, K. Koumoto, T. Kimura, K. Sakurai and S. Shinkai, Biomaterials, 25, 15, 3109-3116 (2004).
    NPL 11: Synthesis and in Vitro Characterization of Antigen-Conjugated Polysaccharide as a CpG DNA Carrier. N. Shimada, K. J. Ishii, Y. Takeda, C. Coban, Y. Torii, S. Shinkai, S. Akira and K. Sakurai, Bioconjugate Chem., 17 1136-1140 (2006).
    NPL 12: Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells, Khan S., et al., J. Biol. Chem., 282, 21145-21159 (2007).
    NPL 13: Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity, Kramer K, et al., Mol. Ther., 25, 62-70 (2017).


SUMMARY OF INVENTION
Technical Problem
It was not known whether peptide/polynucleotide conjugates have apparent immunity induction activity on their own.
The present inventors found that peptide/polynucleotide conjugates which are not complexed with β-1,3-glucan, especially peptide/polynucleotide conjugates comprising a CpG motif, have high immunity induction activity on their own; and thus, the inventors completed the present invention. Therefore, this invention has as its object to provide an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, and a pharmaceutical composition comprising the same.
Solution to Problem
A first aspect of the present invention in accordance with the aforementioned object solves the problems mentioned hereinabove by providing an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide.
In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide may have an amino acid length of not less than 5 but not more than 30.
In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide may have an amino acid length of not less than 8 but not more than 11.
In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs.
In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may have a nucleotide length of not less than 15 but not more than 40.
In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may have a nucleotide length of not less than 20 but not more than 30.
In the immunity-inducing agent according to the first aspect of the present invention, the polynucleotide or polynucleotide derivative may be a polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds.
In the immunity-inducing agent according to the first aspect of the present invention, in the polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, not less than 50% of the phosphodiester bonds may be substituted with phosphorothioate bonds.
In the polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, not less than 90% of the phosphodiester bonds may be substituted with phosphorothioate bonds.
In the immunity-inducing agent according to the first aspect of the present invention, one or both of the covalent bond between the spacer and the polynucleotide or polynucleotide derivative, and the covalent bond between the spacer and the antigenic peptide are preferably a covalent bond(s) that is (are) cleavable in biological environment.
In the immunity-inducing agent according to the first aspect of the present invention, the antigenic peptide which constitutes the polynucleotide/peptide conjugate, and the spacer bound to the polynucleotide or polynucleotide derivative may be bound together via a covalent bond (disulfide bond) produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer.
In the immunity-inducing agent according to the first aspect of the present invention, the spacer may comprise a repeating unit represented by the following formula.




In the above formula,

    
    
        X represents an oxygen atom or a sulfur atom (wherein each X may be the same or different),
        R represents any of (CH2)pO, (CH2)qNH, and (CH2CH2O)m (wherein m, p and q each independently represent a natural number of not more than 10), and
        n represents a natural number of not more than 10.
    
    


In the immunity-inducing agent according to the first aspect of the present invention, the spacer may have a structure represented by any of the following formulas.




In the immunity-inducing agent according to the first aspect of the present invention, it is preferred that the antigenic peptide should have an amino acid length of not less than 5 but not more than 30,

    
    
        that the polynucleotide or polynucleotide derivative should be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs,
        that the polynucleotide derivative should be a polynucleotide derivative in which phosphodiester bonds are at least partially substituted with phosphorothioate bonds, and
        that one or both of the covalent bond between the spacer and the polynucleotide or polynucleotide derivative, and the covalent bond between the spacer and the antigenic peptide have a structure(s) that is (are) a covalent bond(s) that is (are) cleavable in biological environment.
    
    


In the immunity-inducing agent according to the first aspect of the present invention, it is more preferred that the antigenic peptide should have an amino acid length of not less than 8 but not more than 11,

    
    
        that the polynucleotide or polynucleotide derivative should be a polydeoxyribonucleotide (DNA) or a DNA derivative comprising two or more CpG motifs and having a nucleotide length of not less than 20 but not more than 30,
        that the polynucleotide derivative should be a polynucleotide derivative in which not less than 90% of phosphodiester bonds are substituted with phosphorothioate bonds,
        that the antigenic peptide which constitutes the polynucleotide/peptide conjugate, and the spacer bound to the polynucleotide or polynucleotide derivative should be bound together via a covalent bond (disulfide bond) produced by a reaction between a thiol group of a cysteine residue at the N-terminus of the antigenic peptide and a thiol group of the spacer, and
        that the spacer should have a structure represented by any of the following formulas.
    
    






In the immunity-inducing agent according to the first aspect of the present invention, a substance having immunostimulatory activity may be further contained as an adjuvant.
A second aspect of the present invention solves the problems mentioned hereinabove by providing a pharmaceutical composition comprising the immunity-inducing agent according to the first aspect of the present invention.
The second aspect of the present invention may be a pharmaceutical composition for treating tumor.
According to another aspect of the present invention, there is provided a method for treating or preventing a disease, the method comprising administering an effective amount of the immunity-inducing agent according to the first aspect of this invention to a subject in need thereof. In this aspect, the disease may be a tumor.
According to a still another aspect of the present invention, there is provided use of the immunity-inducing agent according to the first aspect of this invention for the production of a medicament for treating or preventing a disease. In this aspect, the disease may be a tumor.
Advantageous Effects of Invention
The peptide/polynucleotide conjugate of the present invention can be used as a highly active immunity-inducing agent having excellent ease of production. Further, immunity-inducing agents having immunity induction activity against a wide variety of antigens can be easily designed by combining an antigenic peptide with a polynucleotide or polynucleotide derivative in an appropriate manner.



BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 depicts the results of the flow cytometric analysis performed in Example 2.
FIG. 2 depicts the results of the flow cytometric analysis performed in Example 3.
FIG. 3 depicts the results of the flow cytometric analysis performed in Example 4.
FIG. 4 depicts the results of the flow cytometric analysis performed in Example 4.
FIG. 5 depicts the results of the flow cytometric analysis performed in Example 5.
FIG. 6 depicts the results of the flow cytometric analysis performed in Example 7.
FIG. 7 depicts the results of the flow cytometric analysis performed in Example 7 comparing cell number as a function of H-2Kb/SIINFEKL (SEQ ID NO: 196).



DESCRIPTION OF EMBODIMENTS
The immunity-inducing agent according to the first aspect of the present invention (hereinafter also abbreviated as “immunity-inducing agent”) comprises, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide.
The peptide/polynucleotide conjugate is a complex in which an antigenic peptide and a polynucleotide or polynucleotide derivative are bound together via covalent bonding. As the “antigenic peptide”, any peptide having any amino acid sequence consisting of any numbers of amino acid residues can be used without particular limitation, as long as it has antigenicity—namely as long as it can be recognized as a foreign substance in the immune system of a living body and elicit specific antibody production (induce an immune response). In this aspect of the present invention, if an antigenic peptide has no cysteine (Cys) in its sequence, a peptide modified by artificially adding one cysteine to the N-terminus of an antigenic epitope peptide derived from an antigenic protein can be used as an antigenic peptide. Examples of the antigenic peptide used to produce the peptide/polynucleotide conjugate serving as an active component of the immunity-inducing agent according to this aspect of the invention include proteins responsible for allergies such as food allergy, pathogens such as bacteria and viruses, and proteins originating from tumor cells and the like, as long as they have a partial amino acid sequence that can act as an epitope. The number of amino acid residues constituting the antigenic peptide is not particularly limited as long as they can act as an epitope, but the number of amino acid residues is commonly in the range of from 5 to 30, and most commonly in the range of approximately from 8 to 17.
The antigenic peptide can be obtained using any known method, such as enzymatic degradation of a protein of origin, or peptide synthesis. Further, the amino acid sequence of the antigenic peptide can be determined using any known method such as epitope analysis with peptide arrays.
Examples of peptides that can be used as antigenic peptides include: MHC-1 T cell epitopes registered on the epitope peptide database IEDB (last accessed: Aug. 11, 2014); the peptides disclosed in the paper written by Chowell, et al. (TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes, PNAS, Apr. 7, 2015, 112 (14), E1754-E1762, Table. S1); and the peptides listed in Tables 1 to 7 below. In this aspect of the present invention, peptides modified by adding one cysteine residue to the N-terminus of such antigenic peptides (except for those antigenic peptides inherently having a cysteine residue in their sequence) can be used as antigenic peptides.







TABLE 1







Diseases to be treated: Infections












MHC
SEQ ID


Antigen
Sequence
subtype
NO.





Human Papilloma virus (HPV) E7
YMLDLQPETT
HLA-A*0201
 1



RAHYNIVTF
H-2 Db
 2


HPV E6
NTLEQTVKK
HLA-A*1101
 3



EVYDFAFRDL
H-2 Kb
 4


 


Hepatitis B virus (HBV) S protein
FLLTRILTI
HLA-A*0201
 5



GLSPTVWLSV
HLA-A*0201
 6



WLSLLVPFV
HLA-A*0201
 7


HBV core protein
FLPSDFFPSV
HLA-A*0201
 8



YVNVNMGLK
HLA-A*11
 9


HBV polymerase
KLHLYSHPI
HLA-A*0201
10



GLSRYVARL
HLA-A*0201
11


HBV polyprotein
KLVALGINAV
HLA-A*0201
12



GVDPNIRTGV
HLA-A*0201
13



ALYDVVTKL
HLA-A*0201
14


HBV HBsAg
VWLSVIWM
H-2 Kb
15


 


Herpes simplex virus (HSV)
SLPITVYYA
HLA-A*0201
16


glycoprotein D
VLLNAPSEA
HLA-A*0201
17



ALLEDPVGT
HLA-A*0201
18


HSV glycoprotein B
RMLGDVMAV
HLA-A*0201
19



NLLTTPKFT
HLA-A*0201
20


 


Cytomegalovirus (CMV) pp65
NLVPMVATV
HLA-A*0201
21



VYALPLKML
HLA-A*2402
22



QYDPVAALF
HLA-A*2402
23


CMV 1E-1
VLEETSVML
HLA-A*0201
24



AYAQKIFKI
HLA-A*2402
25


 


Influenza virus NP
CTELKLSDY
HLA-A*0101
26


Influenza virus M1
GILGFVFTL
HLA-A*0201
27



ILGFVFTLTV
HLA-A*0201
28


Influenza virus HA2
YIGEVLVSV
HLA-A*0201
29


Influenza virus nucleoprotein
KLGEFYNQMM
HLA-A*0201
30


 


Respiratory Syncytial Virus (RSV) M2
YLEKESIYY
HLA-A*0101
31



SYIGSINNI
H-2 Kd
32


RSV NP
KMLKEMGEV
HLA-A*0201
33


RSV F protein
AITTILAAV
HLA-A*0201
34



ALLSTNKAV
HLA-A*0201
35
















TABLE 2







Diseases to be treated: Infections












MHC
SEQ ID


Antigen
Sequence
subtype
NO.






ELDKYKNAV
HLA-A*0201
36



FLLGVGSAI
HLA-A*0201
37



FMNYTLNNT
HLA-A*0201
38



HLEGEVNKI
HLA-A*0201
39



KIMTSKTDV
HLA-A*0201
40



KINQSLAFI
HLA-A*0201
41



SVYDFFVWL
H-2 Kb
42


 


Human Immunodeficiency Virus (HIV)
RYLKDQQLL
HLA-A*2402
43


Env
SLLNATAIAV
HLA-A*0201
44


HIV Gag
SLYNTVATL
HLA-A*0201
45



RTLNAWVKV
HLA-A*0201
46



FLGKIWPS
HLA-A*0201
47



TLNAWVKVV
HLA-A*0201
48



SLFNTVATL
HLA-A*0201
49



SLYNTVATLY
HLA-A*0201
50


 


Polyomavirus VP1
LLMWEAVTV
HLA-A*0201
51


Polyomavirus Large T
LLLIWFRPV
HLA-A*0201
52


 


Human T-cell leukemia virus type 1
LLFGYPVYV
HLA-A*0201
53


(HTLV-1) Tax
SFHSLHLLF
HLA-A*2402
54


 


Epstein-Barr virus (EBV) BRLF1
DYCNVLNKEF
HLA-A*2402
55



TLDYKPLSV
HLA-A*0201
55



YVLDHLIVV
HLA-A*0201
57


EBV LIMP-1
YLLEMLWRL
HLA-A*0201
58



YLQQNWWTL
HLA-A*0201
59
















TABLE 3







Diseases to be treated: Cancers












MHC
SEQ ID


Antigen
Sequence
subtype
NO.





ABL1
QQAHCLWCV
HLA-A*0201
60


 


ACPP
ALDVYNGLL
HLA-A*0201
61


 


ACPP
ALNVYNGLL
HLA-A*0201
62


 


BA46
NLFETPVEA
HLA-A*0201
63


 


BA46
GLQHWVPEL
HLA-A*0201
64


 


BAP31
KLDVGNAEV
HLA-A*0201
65


 


BCL-2
PLFDFSWLSL
HLA-A*0201
66


 


BCL-2
YLNRHLHTWI
HLA-A*0201
67


 


BCL-2
WLSLKTLLSL
HLA-A*0201
68


 


BCL-2
ALSPVPPVV
HLA-A*0201
69


 


BCL-X
YLNDHLEPWI
HLA-A*0201
70


 


BMI1
CLPSPSTPV
HLA-A*0201
71


 


BMI1
TLQDIVYKL
HLA-A*0201
72


 


CAMEL
MLMAQEALAFL
HLA-A*0201
73


 


CB9L2
ALYLMELTM
HLA-A*0201
74


 


CD33
YLISGDSPV
HLA-A*0201
75


 


CEACAM
YLSGANLNL
HLA-A*0201
76


 


DLK1
ILGVLTSLV
HLA-A*0201
77


 


Endosialin
LLVPTCVFLV
HLA-A*0201
78


 


EphA2
TLADFDPRV
HLA-A*0201
79


 


EZH2
YMCSFLFNL
HLA-A*0201
80


 


EZH2
SQADALKYV
HLA-A*0201
81


 


FAPα
ALVCYGPGI
HLA-A*0201
82


 


FAPα
GLFKCGIAV
HLA-A*0201
83


 


FLT1
TLFWLLTL
HLA-A*0201
84


 


FOLR1
EIWTHSYKV
HLA-A*0201
85


 


Glycipan 3
FVGEFFTDV
HLA-A*0201
86


 


gp100
KTWGQYWQV
HLA-A*0201
87


 


gp100
ITDQVPFSV
HLA-A*0201
88


 


gp100
IMDQVPFSV
HLA-A*0201
89


 


gp100
YLEPGPVTV
HLA-A*0201
90


 


HO-1
QLFEELQEL
HLA-A*0201
91


 


Heparanase
LLLGPLGPL
HLA-A*0201
92


 


HER2
ILHDGAYSL
HLA-A*0201
93


 


HER2
LIAHNQVRQV
HLA-A*0201
94
















TABLE 4







Diseases to be treated: Cancers












MHC
SEQ ID


Antigen
Sequence
subtype
NO.





HER2
KIFGSLAFL
HLA-A*0201
 95


 


HMMR
ILSLELMKL
HLA-A*0201
 96


 


IL13Ra
ALPFGFILV
HLA-A*0201
 97


 


IDO
ALLEIASCL
HLA-A*0201
 98


 


ITGB8
ALMEQQHYV
HLA-A*0201
 99


 


KLK
VISNDVCAQV
HLA-A*0201
100


 


Lengsin
FIYDFCIFGV
HLA-A*0201
101


 


LIVIN
QLCPICRAPV
HLA-A*0201
102


 


LMP-1
YLQQNWWTL
HLA-A*0201
103


 


LY6K
LLLASIAAGL
HLA-A*0201
104


 


MAGE-10
GLYDGMEHL
HLA-A*0201
105


 


MAGE-A3
KVAELVHFL
HLA-A*0201
106


 


MAGE-C1
FLAMLKNTV
HLA-A*0201
107


 


MAGE-3
FLWGPRALV
HLA-A*0201
108


 


MAGE-4
GVYDGREHTV
HLA-A*0201
109


 


MAGE-A1
KVLEYVIKV
HLA-A*0201
110


 


MAGE-A2
YLQLVFGIEV
HLA-A*0201
111


 


MART-1
ELAGIGILTV
HLA-A*0201
112


 


MSLN
SLLFLLFSL
HLA-A*0201
113


 


MSLN
VLPLTVAEV
HLA-A*0201
114


 


Midkine
AQCQETIRV
HLA-A*0201
115


 


MS4A1
SLFLGILSV
HLA-A*0201
116


 


NRP-1
GMLGMVSGL
HLA-A*0201
117


 


NY-ESO-1
SLLMWITQC
HLA-A*0201
118


 


NY-ESO-1
SLLMWITQV
HLA-A*0201
119


 


BGLAP
YLYQWLGAPV
HLA-A*0201
120


 


p53
YLGSYGFRL
HLA-A*0201
121


 


p53
KLCPVQLWV
HLA-A*0201
122


 


p53
SLPPPGTRV
HLA-A*0201
123


 


p53
GLAPPQHLIRV
HLA-A*0201
124


 


p53
LLGRNSFEV
HLA-A*0201
125


 


p53
RMPEAAPPV
HLA-A*0201
126


 


p53
STPPPGTRV
HLA-A*0201
127


 


PASD1
YLVGNVCIL
HLA-A*0201
128


 


PASD1
QLLDGFMITL
HLA-A*0201
129
















TABLE 5







Diseases to be treated: Cancers












MHC
SEQ ID


Antigen
Sequence
subtype
NO.





PASD1
ELSDSLGPV
HLA-A*0201
130


 


PIAC1
SIDWFMVTV
HLA-A*0201
131


 


Pr1
VLQELNVTV
HLA-A*0201
132


 


PRAME
ALYVDSLFFL
HLA-A*0201
133


 


PRAME
VLDGLDVLL
HLA-A*0201
134


 


Prominin1
YLQWIEFSI
HLA-A*0201
135


 


PSA
KLQCVDLHV
HLA-A*0201
136


 


PSA
FLTPKKLQCV
HLA-A*0201
137


 


PSCA
AILALLPAL
HLA-A*0201
138


 


PSCA
QLGEQCWTV
HLA-A*0201
139


 


PSMA
SLFEPPPPG
HLA-A*0201
140


 


PSMA
MMNDQLMFL
HLA-A*0201
141


 


PSMA
VLAGGFFLL
HLA-A*0201
142


 


RNF43
ALWPWLLMAT
HLA-A*0201
143


 


SART3
RLAEYQAYI
HLA-A*0201
144


 


STEAP1
MLAVFLPIV
HLA-A*0201
145


 


Survivin
LMLGEFLKL
HLA-A*0201
146


 


Survivin-3a
LTLGEFLKL
HLA-A*0201
147


 


Survivin
TLPPAWQPFL
HLA-A*0201
148


 


TACE
YLIELIDRV
HLA-A*0201
149


 


TARP 2M
FLPSPLFFFL
HLA-A*0201
150


 


TARP
FLFLRNFSL
HLA-A*0201
151


 


Telomerese
YLQVNSLQTV
HLA-A*0201
152


 


Telomerase
ILAKFLHWL
HLA-A*0201
153


 


Telomerase
ALLTSRLRFI
HLA-A*0201
154


 


Telomerase
RLTSRVKAL
HLA-A*0201
155


 


Telomerase
GLLGASVLGL
HLA-A*0201
166


 


TGF I3
RLSSCVPVA
HLA-A*0201
157


 


topII
FLYDDNQRV
HLA-A*0201
158


 


TRAG
GLIQLVEGV
HLA-A*0201
159


 


TRAG
SILLRDAGLV
HLA-A*0201
160


 


Mucin
LLLTVLTVV
HLA-A*0201
161


 


Mucin
LLLLTVLTV
HLA-A*0201
162


 


Tyrosinase
YMDGTMSQV
HLA-A*0201
163


 


WT1
RMFPNAPYL
HLA-A*0201
164
















TABLE 6







Diseases to be treated: Cancers












MHC
SEQ ID


Antigen
Sequence
subtype
NO.





WT1
VLDFAPPGA
HLA-A*0201
165


 


WT1
SLGEQQYSV
HLA-A*0201
166


 


ABL1
CLWCVPQLR
HLA-A*0201
167


 


BCR-ABL
GVRGRVEEI
HLA-A*0201
168


 


HSP105
RLMNDMTAV
HLA-A*0201
169


 


HSP105
KLMSSNSTDL
HLA-A*0201
170


 


CD105
LLTAALWYV
HLA-A*0201
171


 


BCL-2A1
DYLQYVLQI
HLA-A*2402
172


 


C1orf59
GYCTQIGIF
HLA-A*2402
173


 


Carbonic
EYRALQLHL
HLA-A*2402
174


anhydrase





 


DEP DC1
EYYELFVNI
HLA-A*2402
175


 


FOXM1
IYTWIEDHF
HLA-A*2402
176


 


Glycipan 3
EYILSLEEL
HLA-A*2402
177


 


gp100
VYFFLPDHL
HLA-A*2402
178


 


HJURP
KWLISPVKI
HLA-A*2402
179


 


hTOM34p
KLRGEVKQNL
HLA-A*2402
180


 


IL13r
VYYNWQYLL
HLA-A*2402
181


 


KIF20A
KYYLRVRPLL
HLA-A*2402
182


 


KIF20A
VYLRVRPLL
HLA-A*2402
183


 


LY6K
RYCNLEGPPI
HLA-A*2402
184


 


MELK
EYCPGGNLF
HLA-A*2402
185


 


Midkine
RYNAQCQETI
HLA-A*2402
186


 


Nuf2
VYGIRLEHF
HLA-A*2402
187


 


BGLAP
LYQWLGAPV
HLA-A*2402
188


 


p-Cadherin
DYLNEWGSRF
HLA-A*2402
189


 


PSA
CYASGWGSI
HLA-A*2402
190


 


RNF43
NYQPVWLCL
HLA-A*2402
191


 


Survivin
AYACNTSTL
HLA-A*2402
192


 


TTK
SYRNEIAYL
HLA-A*2402
193


 


Tyrosinase
AFLPWHRLF
HLA-A*2402
194


 


WT1
CYTWNQMNL
HLA-A*2402
195


















TABLE 7






Amino acid
SEQ ID


Origin of peptide
sequence
NO.







Ovalbumin (OVA)
SIINFEKL
196


 


Murine melanocyte gp100
EGSRNQDWL
197


 


Human melanocyte gp100
KVPRNQDWL
198


 


CT26 (colon cancer line)
SPSYVYHQF
199


 


Influenza virus HA
IYSTVASSL
200


 


Influenza virus NP
ASNENMDTM
201


 


Influenza virus PA
SSLENFRAYV
202


 


β-galactosidase
DAPIYTNV
203


 


MuLV (Murine leukemia virus) p15E
KSPWFTTL
204


 


SeV (Sendai virus)
FAPGNYPAL
205


 


MCMV (Murine cytomegalovirus) IE1
YPHFMPTNL
206


 


LCMV (Lymphocytic gp33 choriomeningitis
KAVYNFATM
207


virus)




 


LCMV NP396
FQPQNGQFI
208


 


LCMV NP118
RPQASGVYM
209


 


Plasmodium malariae Pb9
SYIPSAEKI
210


 


HIV P18-I10
RGPGRAFVTI
211


 


BCG MPT51
GGPHAVYLL
212


 


Human CEA (Human carcinoembryonic
EAQNTTYL
213


antigen)




 


P815 (Mouse-derived antigen-presenting
LPYLGWLVF
214


cell)




 


HBsAg (Hepatitis B virus antigen)
IPQSLDSWWTSL
215


 


HSV-1 (Murine herpes simplex virus) gB
SSIEFARL
216


 


HY (Male-specific antigen) Uty
WMHHNMDLI
217


 


EGFP (Enhanced green fluorescent protein)
HYLSTQSAL
218


 


HER2
TYLPTNASL
219


 


VSV (Vesicular stomatitis virus) NP
RGYVYQGL
220


 


Polyomavirus MT
RRLGRTLLL
221









As the single-chain polynucleotide or polynucleotide derivative constituting a polynucleotide/peptide conjugate, any polynucleotide or polynucleotide derivative having any nucleotide sequence consisting of any numbers of nucleotides can be used without particular limitation, as long as it comprises one or a plurality of (preferably a plurality of) CpG motifs. Specific examples of CpG motifs include AGCGTT, GACGTT, GACGTC, GTCGTT, and the like. The number of CpG motifs contained in the polynucleotide is not particularly limited, but preferably one to six CpG motifs, more preferably two to four CpG motifs, are contained in the polynucleotide. The polynucleotide or polynucleotide derivative is preferably a polydeoxyribonucleotide (DNA) or a phosphorothioate-modified DNA derivative comprising two or more CpG motifs, but may be partially composed of an RNA or an RNA derivative. When an RNA or an RNA derivative is contained, the content of one or a plurality of such RNAs or RNA derivatives is preferably not more than 20% (specifically not more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1%).
The number of nucleotides contained in the polynucleotide or polynucleotide derivative is in the range of preferably from 15 to 40 (specifically 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40), more preferably from 20 to 30 (specifically 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30). Specific examples of preferred polynucleotides or polynucleotide derivatives include those listed in Table 8 below.









TABLE 8






DNA comprising CpG motifs (5′→3′)




*Phosphodiester bonds are completely
SEQ ID



substituted with phosphorothioate bonds.
NO.







K3
ATCGACTCTCGAGCGTTCTC
222


 


K3-20(b)
GAGCGTTCTCGAGCGTTCTC
223


 


K3-21
CGAGCGTTCTCGAGCGTTCTC
224


 


K3-24
TCTCGAGCGTTCTCGAGCGTTCTC
225


 


K3-27
GACTCTCGAGCGTTCTCGAGCGTTCTC
226


 


K3-30(a)
GAGCGTTCTCATCGACTCTCGAGCGTTCTC
227


 


K3-30(b)
ATCGACTCTCGAGCGTTCTCGAGCGTTCTC
228


 


K3-40
ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC
229


 


K3-30(c)
CTCAGCGTTCTCAGCGTTCTCAGCGTTCTC
230


 


K3-30(d)
TTTAGCGTTTTTAGCGTTTTAGCGTTTTT
231


 


K3-30(e)
TTAGCGTTTAGCGTTTAGCGTTTAGCGTTT
232


 


K3-30(f)
TTAGCGTTTAGCGTTTAGCGTTTAGCGTTT
233


 


K3-26(a)
TCAGCGTTTCAGCGTTTCAGCGTTTC
234


 


K3-26(b)
TTAGCGTTTTAGCGTTTTAGCGTTTT
235


 


ODN1668
TCCATGACGTTCCTGATGCT
236


 


ODN1668-30
TGACGTTCCTTCCATGACGTTCCTGATGCT
237


 


ODN1668-40
TCCATGACGTTCCTGATGCTTCCATGACGTTCCTGATGCT
238


 


ODN1826
TCCATGACGTTCCTGACGTT
239


 


ODN1826-30
TGACGTTCCTTCCATGACGTTCCTGACGTT
240


 


ODN1826-40
TCCATGACGTTCCTGACGTTTCCATGACGTTCCTGACGTT
241


 


ODN2006
TCGTCGTTTTGTCGTTTTGTCGTT
242


 


ODN2006-30
GTCGTTTCGTCGTTTTGTCGTTTTGTCGTT
243


 


ODN2006-40
TCGTCGTTTTGTCGTTTCGTCGTTTTGTCGTTTTGTCGTT
244


 


ODN684
TCGACGTTCGTCGTTCGTCGTTC
245


 


ODN684-30
TCGTCGTTCGACGTTCGTCGTTCGTCGTTC
246


 


ODN684-40
GTTCGTCGTTTCGTCGTTCGACGTTCGTCGTTCGTCGTTC
247


 


ODND-SL01
TCGCGACGTTCGCCCGACGTTCGGTA
248


 


ODND-SL01-35
TCGCGACGTTCGCGACGTTCGCCCGACGTTCGGTA
249









Since the polynucleotide is susceptible to degradation by nuclease in the living body, a polynucleotide derivative may be used instead of the polynucleotide with the aim of enhancing stability in the living body. Examples of the polynucleotide derivative include those derivatives in which the hydroxyl groups at the 2′ position of a ribonucleotide are completely or partially substituted with fluorine or methoxy groups, those derivatives in which the phosphodiester bonds in a polyribonucleotide (RNA) or a polydeoxyribonucleotide (DNA) are completely or partially substituted with phosphorothioate bonds, and the like. In the case of those derivatives in which the phosphodiester bonds in a polyribonucleotide or a polydeoxyribonucleotide are partially substituted with phosphorothioate bonds, it is preferred that not less than 50% (specifically not less than 50, 60, 70, 80 or 90%) of the phosphodiester bonds should be substituted with phosphorothioate bonds, and it is more preferred that not less than 90% (specifically not less than 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%) of the phosphodiester bonds should be substituted with phosphorothioate bonds. The phosphodiester bonds may be substantially completely substituted with phosphorothioate bonds. The positions of phosphodiester bonds to be substituted with phosphorothioate bonds are not particularly limited. Two or more consecutive phosphodiester bonds may be substituted, or phosphodiester bonds may be substituted so as to ensure that phosphorothioate bonds are not adjacent to each other.
The polynucleotide or polynucleotide derivative, which is covalently bound to the antigenic peptide via a spacer, can be bound to any of the N-terminus, C-terminus, and side chains of the antigenic peptide, but it is preferred that the polynucleotide or polynucleotide derivative should be bound toward the N-terminus of the antigenic peptide. If an antigenic peptide contains no Cys residue, a peptide modified by adding a Cys residue to the N-terminus of the antigenic peptide can be used. The polynucleotide or polynucleotide derivative and the antigenic peptide are bound together via a spacer, which is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide. As the reactive functional groups used to form bonding between the spacer and the polynucleotide or polynucleotide derivative or between the spacer and the antigenic peptide, any functional groups present in the antigenic peptide and the polynucleotide or polynucleotide derivative can be used as they are, or any groups that can react with a functional group activated by chemical modification to form covalent bonding can be used. It is preferred that an oxygen atom of the hydroxy group at the 5′ end or 3′ end of the polynucleotide or polynucleotide derivative should be bound to the spacer. Also, it is preferred that a sulfur atom of the sulfhydryl group at the side chain of a Cys residue in the antigenic peptide should be bound to the spacer.
One preferred example of the peptide/polynucleotide conjugate has a structure represented by formula (A) below, in which a region toward the N-terminus of an antigenic peptide is bound via a spacer Sp to a region toward the 3′ end or 5′ end of a polynucleotide or polynucleotide derivative.

[Polynucleotide or polynucleotide derivative]—Sp—[Antigenic peptide]  Formula (A)

Examples of the spacer Sp include alkylene group, polyethylene glycol (PEG), and the like. The spacer may comprise a repeating unit having a phosphodiester structure, as represented by the following formula.




In the above formula, X represents an oxygen atom or a sulfur atom (wherein each X may be the same or different), R represents any of (CH2)pO, (CH2)qNH, and (CH2CH2O)m (wherein m, p and q each independently represent a natural number of not more than 10), and n represents a natural number of not more than 10.
Since such repeating unit do not undergo hydrolysis by nuclease, there occurs no significant decrease in stability in the living body even when X is an oxygen atom. For example, when R is (CH2)3, the size of the repeating unit is nearly equal to that of a ribonucleotide or a deoxyribonucleotide, so that it can be expected that a production cost associated with substitution of part of the polynucleotide or polynucleotide derivative with the spacer can be reduced. Specific examples of the spacer Sp include the following.






















Preferred examples of the spacer Sp include those having any of the following structures.




Examples of a combination of reactive functional groups used to form bonding between the spacer and the polynucleotide or polynucleotide derivative or between the spacer and the antigenic peptide include not only a combination of reactive functional groups used to form ester bonds, amide bonds, phosphoester bonds, or the like, but also a combination of reactive functional groups used to immobilize a biomolecule on a biochip surface. More specific examples thereof are detailed below.
(a) Alkyne and an Azide
Alkyne and an azide form a 1,2,3-triazole ring through a cycloaddition reaction (Huisgen reaction) as illustrated below. These compounds, which are stable functional groups capable of being introduced into many organic compounds including biomolecules, react with each other rapidly and nearly quantitatively even in a solvent including water, and generate no unnecessary wastes with little side effects; thus, they are widely used predominantly in so-called “click chemistry” reactions in the field of biochemistry. An alkyne derivative and an azido group can be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative using any known method. As for the alkyne derivative, those derivatives having a reactive functional group are easily available, such as propargyl alcohols or propargyl amines. By being reacted directly with a reactive functional group such as carboxyl group or hydroxyl group, or reacted with carbonyldiimidazole or the like, such an alkyne derivative can be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative, through amide bonding, ester bonding, urethane bonding, or other bonding formed by the reaction. The azido group can also be introduced into an antigenic peptide or a polynucleotide or polynucleotide derivative using any known method. Additionally, the Huisgen reaction is performed in the presence of a copper catalyst. However, since antigenic peptides, and polynucleotide derivatives in which the phosphodiester bonds are substituted with sulfur-containing functional groups such as phosphorothioate bonds, contain sulfur atoms coordinating to a copper ion, there may occur a deterioration of the catalytic activity of copper. Thus, it is preferred to add an excess amount of copper for the purpose of increasing the rate of reaction.




(b) Maleimide or Vinyl Sulfone and a Thiol Group

Maleimide or vinyl sulfone, which has double bonds adjacent to an electron-withdrawing carbonyl or sulfone group, produces a stable thioether derivative at a near-neutral pH through an addition reaction (Michael addition reaction) with a thiol group as illustrated below. Since maleimide and vinyl sulfone derivatives containing a suitable spacer are commercially available, it is easy to introduce such a functional group into an antigenic peptide or a polynucleotide or polynucleotide derivative. In the case of introduction of a thiol group into an antigenic peptide, when the antigenic peptide contains cysteine, a thiol group at the side chain of the cysteine residue can be utilized. However, since cysteine is an amino acid with low abundance ratio, a peptide modified by introducing cysteine toward the N-terminus of an antigenic peptide is used. As the polynucleotide or polynucleotide derivative containing a thiol group, a thiolated polynucleotide in which the hydroxyl group at the 5′ end is converted to a thiol group is used.




(c) Thiol Group at the Side Chain of Cysteine and Thiol Group of a Thiolated Polynucleotide

As mentioned above, a thiol group at the side chain of a cysteine residue in an antigenic peptide having cysteine introduced toward the N-terminus thereof is reacted with a thiol group of a thiolated polynucleotide to form a disulfide group. Since the disulfide bonding is cleaved in the presence of a reducing agent, this bonding is inferior in stability over those mentioned in the previous sections. The introduction of a thiol group into a polynucleotide or polynucleotide derivative can be performed using any known method. One specific example of such a method is a reaction of an aminated polynucleotide or polynucleotide derivative with a succinimidyl ester of ω-(2-pyridyldithio) fatty acid as illustrated below.




Inter alia, disulfide bonding formed by combination of a thiol group at the side chain of cysteine with a thiol group of a thiolated polynucleotide is preferred since this bonding is easily cleavable in the living body.
The polynucleotide/peptide conjugate used as an active component of the immunity-inducing agent according to this aspect of the present invention can be in a free form or in the form of a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include salts of alkali metals (e.g., potassium, sodium, lithium), salts of alkali earth metals (e.g., calcium, magnesium), ammonium salts (including tetramethylammonium salt, tetrabutylammonium salt), salts of organic amines (e.g., triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine), and acid adduct salts (including inorganic acid salts such as hydrochloride, hydrobromate, hydroiodide, hydrosulfate, phosphate and nitrate; and organic acid salts such as acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate (mesylate), ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, and gluconate). Further examples of pharmaceutically acceptable salts also include hydrates thereof.
The pharmaceutical composition according to the second aspect of the present invention (hereinafter also simply abbreviated as “pharmaceutical composition”) comprises the immunity-inducing agent according to the first aspect of this invention. In order to produce the pharmaceutical composition, the peptide/polynucleotide conjugate as an active component can be used in combination with any known components (any carriers, excipients and additives acceptable for pharmaceutical purposes) and any known pharmaceutical formulation method. In order to produce the pharmaceutical composition comprising an immunity-inducing agent, the peptide/polynucleotide conjugate as an active component can be used in combination with any known components (any carriers, excipients and additives acceptable for pharmaceutical purposes) and any known pharmaceutical formulation method. Examples of pharmaceutical substances include, but are not limited to, the following: amino acids such as glycine, alanine, glutamine, asparagine, arginine or lysine; antioxidants such as ascorbic acid, sodium sulfate or sodium hydrogen sulfite; buffers such as phosphate buffer, citrate buffer, borate buffer, sodium hydrogen carbonate, or Tris-hydrochloride (Tris-HCl) solution; fillers such as mannitol or glycine; chelators such as ethylenediaminetetraacetic acid (EDTA); complexing agents such as caffeine, polyvinylpyrrolidine, β-cyclodextrin or hydroxypropyl-β-cyclodextrin; bulking agents such as glucose, mannose or dextrin; other carbohydrates such as monosaccharides or disaccharides; colorants; flavorants; diluents; emulsifiers; hydrophilic polymers such as polyvinylpyrrolidine; low-molecular-weight polypeptides; salt-forming counterions; preservatives such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide; solvents such as glycerol, propylene glycol or polyethylene glycol; sugar alcohols such as mannitol or sorbitol; suspending agents; surfactants such as sorbitan esters, polysorbates (e.g., polysorbate 20, polysorbate 80), triton, tromethamine, lecithin or cholesterol; stability enhancers such as sucrose or sorbitol; elasticity enhancers such as sodium chloride, potassium chloride, mannitol or sorbitol; transporting agents; excipients; and/or pharmaceutical aids. Such a pharmaceutical substance is preferably added to a pharmaceutical agent in an amount of from 0.01 to 100 times, especially from 0.1 to 10 times, higher than the weight of the pharmaceutical agent. The preferred compositional profile of a pharmaceutical composition prepared as a pharmaceutical preparation can be determined, as appropriate, by any skilled artisan depending on the disease to be treated, the administration route to be applied, and the like.
The pharmaceutical composition is provided in a dosage form suitable for oral or parenteral administration. For example, the pharmaceutical composition is used as an injection, a suppository or the like. Examples of injections include various injection forms such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection and drip infusion. Such injections can be prepared according to known methods. With regard to a method for preparing an injection, the injection can be prepared by, for example, dissolving or suspending the polynucleotide/peptide conjugate of the present invention in a sterile aqueous solvent commonly used for injection. Examples of the aqueous solvent for injection that can be used include distilled water, physiological saline, a buffer such as phosphate buffer, carbonate buffer, Tris buffer or acetate buffer, or the like. The pH of such an aqueous solvent is in the range of from 5 to 10, preferably from 6 to 8. The prepared injection is preferably filled in an appropriate ampule. The injection may be made into a freeze-dried formulation. As for other dosage forms besides injections, the pharmaceutical composition can be provided in a dosage form for transdermal or transmucosal absorption (e.g., liquid spray, ointment, gel, lotion, patch), in a subcutaneous, local, sustained-release dosage form (e.g., suspension containing a nanogel, a biodegradable micro/nano-capsule, etc., temperature-responsive gel), or in the form of a pharmaceutical preparation accompanied with a percutaneous device for skin permeation (e.g., iontophoresis, microneedle), a powder, a tablet, a capsule, a syrup, or an inhalant such as aerosol or dry powder.
The pharmaceutical composition may further comprise a substance having immunostimulatory activity as an adjuvant. The adjuvant is, but not limited to, a substance that activates innate immunity. The adjuvant is preferably an agonist of an innate immunity receptor. Examples of innate immunity receptor agonists include TLR agonists (e.g., TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR7 agonist, TLR8 agonist, TLR9 agonist), RLR (retinoic acid-inducible gene I (RIG-1)-like receptors) agonists, STING (stimulator of Interferon genes) agonists, NLR (nucleotide-binding oligomerization domain (NOD)-like receptors) agonists, and CLR (C-type lectin receptors) agonists. Examples of TLR agonists include lipopeptide, Poly IC RNA, imiquimod, resiquimod, monophosphoryl lipid (MPL), CpG-ODN, and the like. Examples of RLR agonists include pppRNA, Poly IC RNA, and the like. Examples of STING agonists include cGAMP, c-di-AMP, c-di-GMP, and the like. Examples of NLR agonists include iE-DAP, FK565, MDP, murabutide, and the like. Examples of CLR agonists include B-glucan, trehalose-6,6′-dimycolate, and the like. The adjuvant is preferably a TLR agonist, more preferably TLR4 agonist, TLR7 agonist or TLR9 agonist, still more preferably imiquimod, resiquimod, MPL or CpG-ODN. In some embodiments, the adjuvant is imiquimod, MPL or CpG-ODN. The adjuvant is selected as appropriate depending on the type of an antigenic peptide introduced into the peptide/polynucleotide conjugate, or the like. For example, the adjuvant can be CpG DNA or the like, or can be a polynucleotide/β-1,3-glucan complex, as disclosed in International Patent Publication No. WO 2015/118789, which is formed by binding a polynucleotide or polynucleotide derivative containing a partial nucleotide sequence having immunostimulatory activity to a polysaccharide having a β-1,3-glucan backbone via hydrogen bonding, and which has a triple helix structure consisting of one molecular chain of the polynucleotide or polynucleotide derivative and two molecular chains of the polysaccharide having a β-1,3-glucan backbone.
The pharmaceutical composition can be administered to a human or a warm-blooded animal (e.g., mouse, rat, rabbit, sheep, pig, cow, horse, chicken, cat, dog, monkey) by any of oral and parenteral routes. Examples of parenteral routes include subcutaneous, intracutaneous and intramuscular injections, intraperitoneal administration, drip infusion, and spray into nasal mucosa or pharyngeal region.
The dose of the peptide/polynucleotide conjugate serving as an active component of the pharmaceutical composition differs according to activity, the disease to be treated, the type, body weight, sex and age of an animal to be medicated, the severity of a disease, administration method, and/or the like. As an example, in the case of medication of an adult human with a body weight of 60 kg, the daily dose for oral administration is generally in the range of from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, and the daily dose for parenteral administration is generally in the range of from about 0.01 to about 30 mg, preferably from about 0.1 to about 20 mg, more preferably from about 0.1 to about 10 mg. When the pharmaceutical composition is administered to other animals, the dose to be used for such animals is calculated by converting the aforementioned dose into a dose per unit body weight and multiplying the dose per unit body weight by the body weight of an animal to be medicated.
By administering the pharmaceutical composition according to this aspect of the present invention to a patient with a pathogenic infection or a cancer, or a subject predisposed to suffering from a cancer or a pathogenic infection, cytotoxic T lymphocytes (CTLs) present in the medicated patient or subject are activated in an antigen-specific manner to induce antigen-specific antibody production, or namely to induce a protective immune response of a warm-blooded animal (preferably a human), thereby enabling prevention or treatment of the infection or cancer. In other words, the pharmaceutical composition according to this aspect of the invention is useful as a vaccine for the prevention or treatment of diseases such as infections or cancers as mentioned above. In this invention, the terms “tumor(s)” and “cancer(s)” are exchangeably used. Also, in this invention, tumors, malignant tumors, cancers, malignant neoplasms, carcinomas, sarcomas and the like may be collectively referred to as “tumors” or “cancers”. Further, the terms “tumor(s)” and “cancer(s)” may in some cases include pathological conditions classified as pre-cancer stages, such as myelodysplastic syndromes.
The types of tumors to be treated are not particularly limited as long as they are tumors proved to be susceptible to the pharmaceutical composition of the present invention. Examples of tumors to be treated include breast cancer, colon cancer, prostate cancer, lung cancer (including small-cell lung cancer, non-small-cell lung cancer, etc.), stomach cancer, ovarian cancer, cervical cancer, endometrial cancer, corpus uteri cancer, kidney cancer, hepatocellular cancer, thyroid cancer, esophageal cancer, osteosarcoma, skin cancer (including melanoma, etc.), glioblastoma, neuroblastoma, ovarian cancer, head and neck cancer, testicular tumor, bowel cancer, blood cancer (including leukemia, malignant lymphoma, multiple myeloma, etc.), retinoblastoma, pancreatic cancer, and the like.
The pharmaceutical composition according to this aspect of the present invention may be used in combination with other antitumor agents. Examples of other antitumor agents include antitumor antibiotics, antitumor plant extracts, BRMs (biological response modifiers), hormones, vitamins, antitumor antibodies, molecular targeted drugs, alkylating agents, metabolic antagonists, other antitumor agents, and the like.
More specifically, examples of alkylating agents include alkylating agents such as nitrogen mustard, nitrogen mustard N-oxide, bendamustine or chlorambucil; aziridine-based alkylating agents such as carboquone or thiotepa; epoxide-based alkylating agents such as dibromomannitol or dibromodulcitol; nitrosourea-based alkylating agents such as carmustine, lomustine, semustine, nimustine hydrochloride, streptozocin, chlorozotocin or ranimustine; other alkylating agents such as busulfan, improsulfan tosilate, temozolomide or dacarbazine, and the like.
Examples of metabolic antagonists include purine metabolic antagonists such as 6-mercaptopurine, 6-thioguanine or thioinosine; pyrimidine metabolic antagonists such as fluorouracil, tegafur, tegafur-uracil, carmofur, doxifluridine, broxuridine, cytarabine or enocitabine; folate metabolic antagonists such as methotrexate or trimetrexate, and the like.
Examples of antitumor antibiotics include mitomycin C, bleomycin, peplomycin, daunorubicin, aclarbicin, doxorubicin, idarubicin, pirarubicin, THP-adriamycin, 4′-epi-doxorubicin or epirubicin, chromomycin A3 or actinomycin D, and the like.
Examples of antitumor plant extracts and derivatives thereof include vinca alkaloids such as vindesine, vincristine or vinblastine; taxanes such as paclitaxel, docetaxel or cabazitaxel; or epipodophyllotoxins such as etoposide or teniposide, and the like.
Examples of BRMs include tumor necrosis factors or indomethacin, and the like.
Examples of hormones include hydrocortisone, dexamethasone, methylprednisolone, prednisolone, prasterone, betamethasone, triamcinolone, oxymetholone, nandrolone, metenolone, fosfestrol, ethinylestradiol, chlormadinone, mepitiostane or medroxyprogesterone, and the like.
Examples of vitamins include vitamin C or vitamin A, and the like.
Examples of antitumor antibodies or molecular targeted drugs include trastuzumab, rituximab, cetuximab, panitumumab, nimotuzumab, denosumab, bevacizumab, infliximab, ipilimumab, nivolumab, pembrolizumab, avelumab, pidilizumab, atezolizumab, ramucirumab, imatinib mesylate, dasatinib, sunitinib, lapatinib, dabrafenib, trametinib, cobimetinib, pazopanib, palbociclib, panobinostat, sorafenib, crizotinib, vemurafenib, kizaruchinib, bortezomib, carfilzomib, ixazomib, midostaurin, gilteritinib, and the like.
Examples of other antitumor agents include cisplatin, carboplatin, oxaliplatin, tamoxifen, letrozole, anastrozole, exemestane, toremifene citrate, fulvestrant, bicalutamide, flutamide, mitotane, leuprorelin, goserelin acetate, camptothecin, ifosfamide, cyclophosphamide, melphalan, L-asparaginase, aceglatone, schizophyllan, picibanil, procarbazine, pipobroman, neocarzinostatin, hydroxyurea, ubenimex, thalidomide, lenalidomide, pomalidomide, eribulin, tretinoin or krestin, and the like.
Examples of infections to be treated include infections with pathogens such as viruses, fungi or bacteria. Examples of viruses include influenza virus, hepatitis virus, human immunodeficiency virus (HIV), RS virus, rubella virus, measles virus, epidemic parotitis virus, herpesvirus, poliovirus, rotavirus, Japanese encephalitis virus, varicella virus, adenovirus, rabies virus, yellow fever virus, and the like. Examples of bacteria include Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, Hemophilus influenza, Mycobacterium tuberculosis, Streptococcus pneumoniae, Helicobacter pylori, Bacillus anthracis, Salmonella typhosa, Neisseria meningitidis, Bacillus dysenteriae, Vibrio cholerae, and the like. Examples of fungi include fungi of the genus Candida, fungi of the genus Histoplasma, fungi of the genus Cryptococcus, fungi of the genus Aspergillus, and the like. The pharmaceutical composition of the present invention may be used in combination with existing therapeutic agents for such infections.
Administration of the pharmaceutical composition of this aspect of the present invention in combination with an adjuvant or other drugs means ingestion of both of the drugs into the body of a medicated subject within a certain period of time. A single preparation incorporating both of the drugs may be administered, or both of the drugs may be formulated into separate preparations and administered separately. When both of the drugs are formulated into separate preparations, the timings of administration of the separate preparations are not particularly limited, and they may be administered simultaneously or may be sequentially administered at intervals of times or days. When separate preparations are administered at different times or on different days, the order of their administration is not particularly limited. Since separate preparations are generally administered according to their respective administration methods, the numbers of doses of these preparations may be the same or different. Also, when both of the drugs are formulated into separate preparations, the separate preparations may be administered by the same administration method (via the same administration route) or by different administration methods (via different administration routes). Further, both of the drugs are not necessarily present simultaneously in the body, and it is only necessary that both of the drugs should be ingested into the body within a certain period of time (e.g., for one month, preferably for one week, more preferably for a few days, still more preferably for one day). The active component of one preparation may be eliminated from the body at the time of administration of the other preparation.
EXAMPLES
Next, the following describes working examples conducted to confirm the actions and effects of the present invention. As referred to in the following examples, the term “CpG DNA(S)” refers to a DNA derivative (an example of polynucleotide derivative) which has a nucleotide sequence comprising a CpG motif(s) and in which phosphodiester bonds are substituted with phosphorothioate bonds. In the chemical structural formulas shown in the following examples, the nucleotide sequences of polynucleotide derivatives are written in single letter codes with the 5′ end to the left (and the 3′ end to the right), and the amino acid sequences of peptides, except for cysteine at the N-terminus, are written in three letter codes with the N-terminus to the left (and the C-terminus to the right). In the polynucleotide derivatives written in single letter codes, all phosphodiester bonds are substituted with phosphorothioate bonds, and their termini end with an oxygen atom at the 5′- or 3′-hydroxy group of the terminal nucleoside when coupled to a spacer, or end with the entire 5′- or 3′-hydroxy group (including a hydrogen atom) of the terminal nucleoside when not coupled to a spacer. Further, in the following examples, the CpG DNA(S)-peptide conjugate was prepared in the form of a salt having triethylamine and acetic acid added thereto.
Example 1: Preparation of a CpG DNA(S)-Peptide Conjugate
One mol of amino group-modified CpG DNA(S) synthesized by a given method known in the art (a CpG DNA(S) derivative having introduced at its 5′ end an amino group with a structure represented by the following formula; nucleotide sequence:









(SEQ ID NO: 229



ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC;






hereinafter abbreviated as “CpG40 (S)”); all phosphodiester bonds were substituted with phosphorothioate bonds) was mixed with 30 mol of succinimidyl 6-[3′-(2-pyridyldithio)-propionamido]hexanoate (LC-PDP) in a phosphate buffer (pH 8.0). After being left to stand at 40° C. for 3 hours, SPDP-modified CpG DNA(S) was purified using a NAP-5 column.





Hereinafter, the structure represented by the following formula is abbreviated as “ssH amino linker”.




A peptide (amino acid sequence: CSIINFEKL (SEQ ID NO: 250; hereinafter abbreviated as “OVApep9”)) having cysteine added toward the N-terminus of an ovalbumin (OVA)-derived antigenic peptide (257th to 264th amino acids (amino acid sequence: SIINFEKL (SEQ ID NO:196))) was mixed at a ratio of 25 mol to 1 mol of the SPDP-modified CpG DNA(S) in an aqueous solution of 30% N,N-dimethylformamide (DMF). After being left to stand at 40° C. for 3 hours, the mixture was fractionated by HPLC to obtain a CpG DNA(S)-peptide conjugate. HPLC was performed under the following gradient conditions using 0.1 M triethylammonium acetate (TEAA; pH 7.0) and acetonitrile as solvents A and B, respectively, and the column ZORBAX Eclipse Plus C18.

















  0 min
A: 90% 
B: 10%



to 25 min
A: 70% 
B: 30%



to 30 min
A: 0%
B: 100%










During the process of the HPLC fractionation of the solution obtained after the reaction of SPDP-modified CpG DNA(S) with the OVA-derived peptide, detection was performed by monitoring the absorption at 260 nm for dA40 (S). It was observed that the elution time of the peak of the fractionated CpG DNA(S)-peptide conjugate was delayed as compared to that of SPDP-modified CpG DNA(S). This is considered to be because the elution time became later since SPDP-modified CpG DNA(S) was bound to the hydrophobic peptide. Further, in the chromatogram obtained from the fractionation, no peak for unreacted SPDP-modified CpG DNA(S) was observed, and only the peak for the CpG DNA(S)-peptide conjugate was detected—this fact confirmed that the CpG DNA(S)-peptide conjugate of interest (CpG40 (S)-OVApep9 conjugate; see below for its structural formula) was obtained in high purity.




Example 2: Evaluation of Induction of Cytotoxic T Lymphocytes by CpG DNA(S)-Peptide Conjugate
The CpG DNA(S)-peptide conjugate was intracutaneously administered as an antigen to mice (C57BL/6 mice (♀, 7 weeks old)) (once at 20 ng per mouse). After one week of administration, splenocytes were isolated from those mice of the same strain not receiving administration, and divided into two groups. To one group, an ovalbumin (egg albumin, OVA)-derived antigenic peptide (peptide sequence: SIINFEKL (SEQ ID NO: 196)) was added, and the mixture was left to stand for 90 minutes to prepare antigen-retaining splenocytes. The other group of splenocytes not receiving addition of the peptide was regarded as non-antigen-retaining splenocytes. Both of the antigen-retaining splenocytes and the non-antigen-retaining splenocytes were fluorescently modified with 5,6-carboxyfluorescein succinimidyl ester (CFSE). During this process, the concentration of CFSE was varied such that the fluorescence intensity of the antigen-retaining splenocytes (CFSE: 5 μM) was higher than that of the non-antigen-retaining splenocytes (CFSE: 0.5 μM). The same numbers of the antigen-retaining and non-antigen-retaining splenocytes were mixed together, and administered via tail vain to the mice administered the CpG DNA(S)-peptide conjugate as an antigen, after one week of administration. The dose of the CpG DNA(S)-peptide conjugate was 20 ng per mouse in terms of peptide (250 ng in terms of CpG40 (S)).
After the lapse of 24 hours from the tail vein administration, splenocytes were isolated from the mice, and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes. The results of the flow cytometric analysis are shown in FIG. 1(FIG. 1(b)). For comparison's sake, the results of the flow cytometric analysis conducted for the control groups under the same conditions are also shown in FIG. 1; as the control groups, other mice were either administered PBS (phosphate-buffered saline) (FIG. 1(a)) or separately administered the antigenic peptide and CpG DNA(S) (FIG. 1(c)), instead of the CpG DNA(S)-peptide conjugate.
As shown in FIG. 1(a), the splenocytes collected from the mice administered PBS contained the same numbers of antigen-retaining and non-antigen-retaining splenocytes. However, as shown in FIG. 1(b), about 95% of antigen-retaining splenocytes disappeared from the splenocytes collected from the mice administered the CpG DNA(S)-peptide conjugate. This revealed that administration of the CpG DNA(S)-peptide conjugate resulted in induction of a peptide antigen-specific immune response. Also, by comparison with FIG. 1(c), it was found that the effect of administration of the CpG DNA(S)-peptide conjugate was higher than that of separate administration of the antigenic peptide and CpG DNA(S).
Example 3: Dependence on the Dose of a CpG DNA(S)-Peptide Conjugate
Mice were immunized with varied doses of the CpG DNA(S)-peptide conjugate. Then, as in Example 2, the same numbers of antigen-retaining and non-antigen-retaining splenocytes were mixed together, and administered via tail vain to the mice administered the CpG DNA(S)-peptide conjugate. Thereafter, splenocytes were isolated from the mice, and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes.
The results of the flow cytometric analysis are shown in FIG. 2. It was found that as the dose of the CpG DNA(S)-peptide conjugate was decreased to less than 20 ng in terms of peptide, the effect of the conjugate diminished gradually. In general, peptide immunization requires administration of the peptide at a dose of several micrograms. However, by the use of the CpG DNA(S)-peptide conjugate prepared in Example 1, the peptide dose was successfully reduced to a hundredth to a thousandth.
Example 4: Dependence on the Nucleotide Length and Nucleotide Sequence of CpG DNA(s) Contained in a CpG DNA(S)-Peptide Conjugate
Different CpG DNA(S)-peptide conjugates were prepared by the same procedure as in Example 1, except that the 40-nucleotide-long CpG DNA(S) derivative (nucleotide sequence: ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC (SEQ ID NO: 229; hereinafter abbreviated as “CpG40 (S)”)), which was used to prepare a CpG DNA(S)-peptide conjugate in Example 1, was replaced with any of the following CpG DNA(S) derivatives: 30-nucleotide-long CpG DNA(S) derivatives (nucleotide sequence:

    
    
        GAGCGTTCTCATCGACTCTCGAGCGTTCTC (SEQ ID NO: 227; hereinafter abbreviated as “CpG30 (S) a”), and nucleotide sequence:
        ATCGACTCTCGAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 228; hereinafter abbreviated as “CpG30 (S) b”)); a 24-nucleotide-long CpG DNA(S) derivative (nucleotide sequence:
        TCTCGAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 225; hereinafter abbreviated as “CpG24 (S)”)); and 20-nucleotide-long CpG DNA(S) derivatives (nucleotide sequence:
        ATCGACTCTCGAGCGTTCTC (SEQ ID NO: 222; hereinafter abbreviated as “CpG20 (S) a”, and nucleotide sequence: GAGCGTTCTCGAGCGTTCTC (SEQ ID NO: 223; hereinafter abbreviated as “CpG20 (S) b”)) (see below for their structural formulas) (as for the structural formulas and nucleotide sequences of these derivatives, see the structural formulas and Table 9 shown below; the nucleotide sequences indicated in boldface with underline in Table 9 are CpG motifs; all phosphodiester bonds were substituted with phosphorothioate bonds).
    
    











TABLE 9





Abbreviated

SEQ ID


name
Nucleotide sequence
NO.







CpG40(S)
ATCGACTCTCGAGCGTTCTCATCGACTCTCGAGCGTTCTC
229


 


CpG30(S)a
GAGCGTTCTCATCGACTCTCGAGCGTTCTC
227


 


CpG30(S)b
ATCGACTCTCGAGCGTTCTCGAGCGTTCTC
228


 


CpG24(S)
TCTCGAGCGTTCTCGAGCGTTCTC
225


 


CpG20(S)a
ATCGACTCTCGAGCGTTCTC
222


 


CpG20(S)b
GAGCGTTCTCGAGCGTTCTC
223













Mice were immunized with the different CpG DNA(S)-peptide conjugates comprising different nucleotide lengths of CpG DNA(S) (20 ng per mouse in terms of peptide), and then, as in Example 2, administered a mixture of antigen-retaining and non-antigen-retaining splenocytes by tail vein injection and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes.
The results of the flow cytometric analysis are shown in FIGS. 3 and 4. It was found that even in the case of CpG DNA(S) shorten to 30 nucleotides, antigen-retaining splenocytes completely disappeared. With regard to CpG DNA(S) shorten to 20 nucleotides, no decrease in the number of antigen-retaining splenocytes was observed in the case of CpG DNA(S) containing only a single CpG motif, whereas a decrease in the number of antigen-retaining splenocytes was observed in the case of CpG DNA(S) containing two CpG motifs, which indicates that the activity of peptide-specific cytotoxic T lymphocytes was induced.
Example 5: Dependence on the Amino Acid Length of a Peptide Contained in a CpG DNA(S)-Peptide Conjugate
Different CpG DNA(S)-peptide conjugates were prepared using a 18-amino acid-long peptide (amino acid sequence: CEVSGLEQLESIINFEKL (SEQ ID NO: 251; hereinafter abbreviated as “OVApep18”)) or a 27-amino acid-long peptide (amino acid sequence: CMSMLVLLPDEVSGLEQLESIINFEKL (SEQ ID NO: 252; hereinafter abbreviated as “OVApep27”)), which were generated by extending the antigenic peptide used in the CpG DNA(S)-peptide conjugate of Example 1 in a direction toward the N-terminus (see below for the structural formulas of the two conjugates). Mice were immunized with the different CpG DNA(S)-peptide conjugates (20 ng per mouse in terms of peptide), and then, as in Example 2, administered a mixture of antigen-retaining and non-antigen-retaining splenocytes by tail vein injection and evaluated for induced cytotoxic T lymphocyte activity through flow cytometrically quantifying the percentages of antigen-retaining and non-antigen-retaining splenocytes to determine the amount of decrease in antigen-retaining splenocytes.




The results of the flow cytometric analysis are shown in FIG. 5. It was observed that the activity of peptide-specific cytotoxic T lymphocytes tends to decrease when the length of the antigenic peptide is extended to 18 or 27 amino acids.
Example 6: Dependence on the Spacer Structure and the Conjugation Site of Peptide in a CpG DNA(S)-Peptide Conjugate
Evaluation of induced cytotoxic T lymphocyte activity was conducted by the same procedure as in Example 2 by using three different CpG DNA(S)-peptide conjugates as detailed below: a CpG DNA(S)-peptide conjugate which was prepared using an amino linker with the structure shown below (hereinafter abbreviated as “C6 amino linker”) instead of the ssH amino linker used to prepare the CpG DNA(S)-peptide conjugate of Example 1 (hereinafter referred to as “Compound (I)”); a CpG DNA(S)-peptide conjugate in which a PEGylated C18 spacer was inserted between CpG DNA(S) and the ssH amino linker; and a CpG DNA(S)-peptide conjugate in which an antigenic peptide was covalently bound to the 3′ end, not to the 5′ end, of CpG DNA(S) via the same spacer structure as used in Compound (I). As a result, it was observed that immunization with any of these conjugates resulted in induction of potent peptide-specific cytotoxic T lymphocyte activity to comparable levels to immunization with the CpG DNA(S)-peptide conjugate prepared in Example 1.




Example 7: Evaluation of the Amount of Antigen Presented on Peritoneal Macrophages
Peritoneal macrophages collected from mice were placed in 48-well plates (1.5×105 cells/well). Different CpG DNA(S)-peptide conjugates prepared using different amino acid lengths of antigenic peptides (OVApep9, OVApep18, OVApep27) and different nucleotide lengths of CpG DNA(S) (CpG40 (S), CpG30 (S) a, CpG30 (S) b, CpG20 (S) a) were added to the wells at a concentration of 2 μg/mL in terms of peptide, followed by culturing for 24 hours. After the culturing, an antibody specific for the OVApep8-MHC molecular complex (fluorescently labeled with phycoerythrin (PE); hereinafter abbreviated as “PE labelled H-2Kb/FIINFEKL” (FIINFEKL (SEQ ID NO:196)) was added, and antibody-bound peritoneal macrophages were quantified by flow cytometry to evaluate the amount of antigen presented.
The results of the flow cytometric analysis are shown in FIGS. 6 and 7. The results demonstrated that the nucleotide length of CpG DNA(S) has little effect on the amount of antigen presented, and that the amount of antigen presented tends to decrease as the antigenic peptide is extended to a length of 18 or 27 amino acids. Also, from the result obtained in FIG. 7 for “CpG40 (S)-PEG-OVApep9”, which is a CpG40 (S)-OVApep9 conjugate having a polyoxyethylene group inserted into a spacer, it was observed that the polyoxyethylene group inserted into the spacer has little effect on the amount of antigen presented.